v3.26.1
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Operating expenses:            
Number of reportable segments | segment         1  
Number of operating segments | segment         1  
Total Firmonertinib $ 42,339   $ 27,720   $ 79,957 $ 89,009
Net loss 49,893 $ 43,320 31,399 $ 64,387 93,213 95,786
Life science            
Operating expenses:            
Research and development: Early-stage programs 13,383   3,625   25,690 44,606
Research and development: Personnel-related and other internal costs 11,009   7,612   21,237 13,617
General and administrative: Personnel-related costs 6,590   3,461   12,773 6,792
General and administrative: Other costs 3,762   2,443   6,071 4,594
Other segment items (2,798)   (2,224)   (5,588) (4,609)
Net loss $ 49,893   $ 31,399   $ 93,213 $ 95,786
Description of other segment item Other segment items consists of interest and investment income.   Other segment items consists of interest and investment income.   Other segment items consists of interest and investment income. Other segment items consists of interest and investment income.
Life science | Firmonertinib            
Operating expenses:            
Other Firmonertinib costs $ 1,447   $ 3,773   $ 5,331 $ 6,034
Total Firmonertinib 17,947   16,482   33,030 30,785
Life science | Further            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs): 1,612   2,848   3,350 5,443
Life science | Favour            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs): 96   71   427 73
Life science | Phase 3 Trials            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs): $ 14,792   $ 9,790   $ 23,922 $ 19,235